Active Stocks
Thu Apr 18 2024 15:59:07
  1. Tata Steel share price
  2. 160.00 -0.03%
  1. Power Grid Corporation Of India share price
  2. 280.20 2.13%
  1. NTPC share price
  2. 351.40 -2.19%
  1. Infosys share price
  2. 1,420.55 0.41%
  1. Wipro share price
  2. 444.30 -0.96%
Business News/ Science / Health/  BDR Pharma launches Favipiravir at 63 per tablet for treatment of COVID-19
BackBack

BDR Pharma launches Favipiravir at ₹63 per tablet for treatment of COVID-19

BDR Pharma's antiviral drug 'BDFAVI' is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at ₹630 per strip

Favipiravir was originally developed by Japan's Fujifilm Holdings Corp under the brand name Avigan for treating influenza.Premium
Favipiravir was originally developed by Japan's Fujifilm Holdings Corp under the brand name Avigan for treating influenza.

NEW DELHI : BDR Pharmaceuticals, a Mumbai based drug company, on Wednesday announced the launched its antiviral drug Favipiravir for the treatment of coronavirus patients in India. The drug has been launched under the brand name 'BDFAVI'.

The 'BDFAVI' drug is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at 630 per strip, BDR Pharmaceuticals said.

The company has also come up with a patient assistance programme which will allow patients and institutions who have limited resources to purchase the medicine at a highly subsidised rate, the BDR Pharma said in a statement.

BDR pharma has received an approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat mild to moderate patients with COVID-19 symptoms. Favipiravir was originally developed by Japan's Fujifilm Holdings Corp under the brand name Avigan for treating influenza.

"BDR has been at the forefront in benefiting patients in this pandemic and supporting India's fight against COVID-19.

This launch further strengthens our commitment to the patients to provide better outcomes for patients with mild to moderate COVID symptoms in India," BDR Pharmaceuticals CMD Dharmesh Shah said.

Separately, pharma major Lupin Limited also announced the the launch of its Favipiravir in India under the brand name Covihalt for the treatment of mild to moderate COVID-19. It is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs. 49 per tablet.

Another drug major Sun Pharma on Tuesday said it has launched antiviral drug Favipiravir under the brand name 'FluGuard' for the treatment of mild to moderate cases of COVID-19, at 35 per tablet in India.

The stocks of FluGuard will be available in the market from this week, Sun Pharma said in a regulatory filing.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 05 Aug 2020, 03:00 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App